SCHEMBL7542895

SCHEMBL7542895

O=C(O)c1c[nH]c2cc(N3CCN(C/C=N/O)CC3)c(F)cc2c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.46
KDM4E B2RXH2 7/20 0.46
HSD17B10 Q99714 5/20 0.46
HPGD P15428 5/20 0.46
LMNA P02545 4/20 0.46
MAPT P10636 3/20 0.46
DRD3 P35462 1/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
USP2 O75604 1/20 0.42
POLB P06746 1/20 0.42
PTPN7 P35236 1/20 0.42
TOP2B Q02880 3/20 0.42
CYP1A2 P05177 1/20 0.42
TOP2A P11388 1/20 0.42
CYP2C9 P11712 1/20 0.42
BRD4 O60885 1/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
CYP2J2 P51589 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7542900 1.00 ALDH1A1 (0.46) ALDH1A1KDM4EHSD17B10HPGDLMNA
SCHEMBL10743065 0.82 KDM4E (0.50) ALDH1A1KDM4EHSD17B10HPGDLMNA
SCHEMBL3401906 0.82 KDM4E (0.52) ALDH1A1KDM4EHSD17B10HPGDLMNA
SCHEMBL9626251 0.82 KDM4E (0.47) ALDH1A1KDM4EHSD17B10HPGDLMNA
SCHEMBL9379704 0.82 ALDH1A1 (0.58) ALDH1A1KDM4EHSD17B10HPGDLMNA
SCHEMBL17475410 0.81 KDM4E (0.51) ALDH1A1KDM4EHSD17B10HPGDLMNA
SCHEMBL3341252 0.80 KDM4E (0.58) ALDH1A1KDM4EHSD17B10HPGDLMNA
SCHEMBL5307312 0.79 KDM4E (0.49) ALDH1A1KDM4EHSD17B10HPGDLMNA
SCHEMBL21111089 0.79 HSD17B10 (0.51) ALDH1A1KDM4EHSD17B10HPGDLMNA
Cyclopropane SCHEMBL3447310 0.78 ALDH1A1 (0.56) ALDH1A1KDM4EHSD17B10HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6492373-B2 FOR TREATMENT OF BACTERIAL INFECTIONS AND/OR RENAL CANCER DISEASES PHARMACEUTICAL INDUSTRY TECHNOLOGY AND DEVELOPMENT CENTER (TW) 2002-12-10 US disclosed
US-6492373-B2 FOR TREATMENT OF BACTERIAL INFECTIONS AND/OR RENAL CANCER DISEASES PHARMACEUTICAL INDUSTRY TECHNOLOGY AND DEVELOPMENT CENTER (TW) 2002-12-10 US disclosed
US-6492373-B2 FOR TREATMENT OF BACTERIAL INFECTIONS AND/OR RENAL CANCER DISEASES PHARMACEUTICAL INDUSTRY TECHNOLOGY AND DEVELOPMENT CENTER (TW) 2002-12-10 US disclosed
US-20020061895-A1 6-fluoro-1,4-dihydro-7-[4-(2-hydroxyiminoethyl)-1-piperazinyl]-4-oxoquinoline-3-carboxylic acid derivatives, their preparation and pharmaceutical compositions PHARMACEUTICAL INDUSTRY TECHNOLOGY 2002-05-23 US disclosed
US-20020061895-A1 6-fluoro-1,4-dihydro-7-[4-(2-hydroxyiminoethyl)-1-piperazinyl]-4-oxoquinoline-3-carboxylic acid derivatives, their preparation and pharmaceutical compositions PHARMACEUTICAL INDUSTRY TECHNOLOGY 2002-05-23 US disclosed
US-20020061895-A1 6-fluoro-1,4-dihydro-7-[4-(2-hydroxyiminoethyl)-1-piperazinyl]-4-oxoquinoline-3-carboxylic acid derivatives, their preparation and pharmaceutical compositions PHARMACEUTICAL INDUSTRY TECHNOLOGY 2002-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061895-A1 6-fluoro-1,4-dihydro-7-[4-(2-hydroxyiminoethyl)-1-piperazinyl]-4-oxoquinoline-3-carboxylic acid derivatives, their preparation and pharmaceutical compositions ATP6V1B1, GLS, RCC2 ALDH1A1 234/4885KDM4E 1113/4885HSD17B10 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.